Combined Hormonal Contraceptives (CHC) Market Trends and 2019 Opportunities Explored in New Global Research Report
DALLAS, January 20, 2015 /PRNewswire/ --
MarketReportsOnline.com adds Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19) industry research report of 64 pages to the life sciences intelligence collection of its research library.
The report titled "Global Combined Hormonal Contraceptive (CHC) Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of the global CHC market with detailed analysis of market sizing and growth, market share and economic impact of the industry. The report also assesses key opportunities in the market and outlines the factors that are and will be driving growth of the industry. Growth of the overall CHC industry has also been forecasted for the period 2014-19, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. An insight into strategic issues affecting key brands on the market is provided followed by an analysis of the leading companies in the hormonal contraceptives market. The report also analyzes the key CHC products in pipeline. Further, key players of the industry like Agile Therapeutics; Bayer Healthcare; Teva Pharmaceuticals and Actavis PLC; are analyzed in the report.
Combined Hormonal Contraceptives (CHC) is widely being used as an effective and reversible birth control method. Mainly used for preventing pregnancies but sometimes also used for treating acne vulgaris, endometriosis, polycystic ovarian syndrome and irregular menstrual flow, CHC works by preventing ovulation i.e. release of egg from ovaries. The hormones are provided in the combined pill, patch or ring.
Most popular Combined Hormonal Contraceptives products are Nuvaring and Ortho Evra. CHC products are broadly used throughout the world by women in the age-group of 15 to 49 years. With increasing health consciousness and awareness, adoption of CHC products or birth control methods is increasing in lesser privileged economic segments too. The growth of CHC market is driven by urbanization and increasing user awareness, rise in menstruating population globally and initiatives taken by governments to encourage the use of contraception. Major trends prevailing in the market are the increasing number of mergers and acquisitions in this business space and demand for reversible method of contraception with fewer side effects.
Country Coverage of this CHC market report: United States, United Kingdom, India, China and Japan.
Company Coverage for this combined hormonal contraceptives industry research: Agile Therapeutics Inc., Actavis Plc., Bayer Healthcare and Teva Pharmaceuticals.
Order a copy of Global Combined Hormonal Contraceptives (CHC) Market: Trends and Opportunities (2014-19) industry research report at http://www.marketreportsonline.com/contacts/purchase.php?name=394315 .
Classification of the CHC market done for this research includes Combined Oral Contraceptive Pills, Combined Vaginal Rings, Combined Transdermal Patches, Combined Injectable Birth Control and Combined Emergency Contraceptive Pills. Market drivers like Rise in Healthcare Expenditure, Growth in the U.S. Contraceptive Market, Government Initiatives and Prescriber Base is Easily Targeted are discussed in this report. Comprehensive Table of Contents, list of figures mentioned in this report and more is available at http://www.marketreportsonline.com/394315-toc.html .
A Strategic SWOT Analysis Review of Teva Pharmaceuticals USA, Inc. provides an in-depth strategic analysis of the company's businesses and operations. The profile will give a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps formulate strategies that augment businesses by enabling to understand partners, customers and competitors better. Key 2014 developments of the company discussed in this research include: Pharmaceutical Company to Pay $27.6 Million to Settle Allegations Involving False Billings to Federal Health Care Programs, A.G. Schneiderman Announces Settlement With Generic Pharmaceutical Companies For Entering Into Anticompetitive Arrangement and Ranbaxy And Teva Settle New York Antitrust Claims. This is a 'profile on demand' report and available at http://www.marketreportsonline.com/262667.html .
A deals and alliances profile report on Agile Therapeutics, Inc. - Pharmaceuticals & Healthcare company provides comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions. The company develops contraceptive products based on proprietary and patented transdermal technology for healthcare industry. Its product, Twirla is a once-weekly contraceptive patch designed to provide convenience and compliance. Agile's technology, Skinfusion consists of an active and a peripheral adhesive system designed to allow stable drug delivery and dependable adhesion. The company also provides contraceptive patch regimens and a progestin-only contraceptive patch that utilize Skinfusion. Agile is headquartered in Princeton, New Jersey, the US. Read more at http://www.marketreportsonline.com/275946.html .
Explore more reports on pharmaceuticals market and related segments at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html .
About Us:
MarketReportsOnline.com is a digital library of 500,000+ syndicated market research reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.
Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
Share this article